TIDMROQ
RNS Number : 9238R
Roquefort Therapeutics PLC
06 March 2023
6 March 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Formation of Scientific Advisory Board to Support Strategy
Depth of scientific and medical experience
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class
medicines in the high value and high growth oncology market , is
pleased to announce the formation of its Scientific Advisory Board
("SAB").
With the Company's focus on the market niche of the cancers that
are resistant to existing medicines, developing innovative,
patented medicines to target novel cancer targets or
immunotherapies to enhance the body's anti-cancer response, the SAB
will initially comprise of Professor Jo Martin, Professor Trevor
Jones and Professor Armand Keating, who together are a team of
researchers, biopharmaceutical innovators and clinicians with an
emphasis on linking pre-clinical research, clinical trials,
production of medicines and the care of patients . The Company aims
to use its drug development expertise to complete pre-clinical
development to reach valuation milestones for licensing
transactions or sale of a clinical program.
The SAB will work closely with the Company's Group Chief
Scientific Officer, Professor Sir Martin Evans to provide
scientific guidance on the Company's strategy as it approaches key
pre-clinical milestones and its approach to clinical trials.
Professor Jo Martin CBE
Professor Martin is Professor of Pathology and Deputy Vice
Principal Health at Queen Mary, University of London and National
Speciality Advisor Pathology NHS England and Improvement. Prof.
Martin qualified at Cambridge University and London Hospital
Medical College, and has a University of London PhD and Masters in
Leadership. She has over 130 published papers including in Nature
Group and Science. She is an award winning eCPD app designer and
co-founder of Biomoti, a drug delivery development ovarian cancer
company. Prof. Martin developed and leads an innovative
multi-million pound adaptive learning programme for RCPath and
Health Education England. Prof. Martin served as a director on the
Board of Barts Health NHS Trust for 5 years. She has broad
experience in healthcare management including responsibility for
local and regional research and for the training and education of
over 17,500 staff. Previously Prof. Martin was National Clinical
Director of Pathology for NHS England April 2013-16, and President
of the Royal College of Pathologists from November 2017-2020, and
is now National Specialty Advisor for Pathology for NHS England and
Improvement, chairing the national Pathology Board and the national
Pathology Workforce Board. Prof. Martin has led the profession
during the pandemic and subsequent incidents related to global and
national pressures. She has worked with international charities,
including as Chair of the Research Advisory Board of the Motor
Neuron Disease Association.
Professor Trevor Jones CBE
Professor Jones has been a scientific advisor to the Company
since February 2022. Prof. Jones has had a distinguished career in
the pharmaceutical and biotech industry spanning over 45 years,
having previously been main Board Director for Research &
Development at The Wellcome Foundation (Wellcome plc), where he was
responsible for the development of a number of significant products
across several therapeutic areas attracting reimbursement, as well
as OTC formulations. Prof. Jones also served as a Non-Executive
Director of Allergan Inc from 2004 to 2015 during which time the
company made a number of key acquisitions. During Prof. Jones's
career, he has served on the Boards of a number of other private
and publicly listed companies and industry bodies across the UK,
USA and Europe. In particular, he was a former Director General of
the Association of the British Pharmaceutical Industry where he
directed all the activities related to UK pharmaceutical industry
government relations on behalf of national and international
pharmaceutical companies. For 12 years he was a member of The UK
Government Regulatory Agency, The Medicines Commission and Chair of
the UK Government Advisory Group on Genetics Research. He was also
a member of the Scientific Board of the EU Life Sciences Innovative
Medicines Initiative (IMI). More recently, Prof. Jones joined the
Board of Ascension as a Non-Executive Director, helping advise the
company on product development and its commercial activities
related to haemophilia and osteoarthritis. He also serves as an
adviser to the UK Government on public health matters including
COVID-19.
Professor Armand Keating
Professor Keating has been an independent medical advisor to the
Company since September 2022. Prof. Keating is an internationally
recognised leader in blood and marrow transplantation and cell
therapy. He is a Professor of Medicine and of Biomedical
Engineering at the University of Toronto. Previously Prof. Keating
was President of the American Society of Hematology and President
of the American Society for Blood and Marrow Transplantation. He
has served in a number of advisory roles at the US National
Institutes of Health and more recently for the New Organ Alliance
and NASA. He held the position of Chief, Medical Services at
Princess Margaret Hospital for a decade and was the Division
Director of Hematology at the University of Toronto. His research
and clinical interests focus on cell-based tissue regeneration,
anti-cancer cell therapy, and blood and marrow transplantation. He
has conducted laboratory, translational and clinical research in
these areas, particularly on the biology and clinical application
of mesenchymal stromal cells and NK cells.
Roquefort Therapeutics Group Chief Scientific Officer, Professor
Sir Martins Evans said, "I am looking forward to working with
Professors Jo Martin, Trevor Jones and Armand Keating who have a
wealth of experience in medical research and drug development. Each
member of the SAB brings unrivalled scientific expertise and
knowledge that will be invaluable as we progress our novel
anti-cancer programs. The formation of the Roquefort Therapeutics
Scientific Advisory Board is an important step forward for the
Company in what is an exciting period."
-Ends-
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3918
Reginald (CEO) 8633
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of four best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
-- MK cell therapy with direct and NK-mediated anti-cancer action.
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDUPURGWUPWGAA
(END) Dow Jones Newswires
March 06, 2023 02:00 ET (07:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Apr 2024 to May 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2023 to May 2024